Study title: Ozcan Z, Burak Z, Kumanlioğlu K, Sabah D, Başdemir G, Bilkay B, Cetingül N, Ozkiliç H. Assessment of chemotherapy-induced changes in bone sarcomas: clinical experience with 99Tcm-MDP three-phase dynamic bone scintigraphy. Nucl Med Commun. 1999 Jan;20(1):41-8. Ozcan Z, Burak Z, Kumanlioğlu K, Sabah D, Başdemir G, Bilkay B, Cetingül N, Ozkiliç H. Assessment of chemotherapy-induced changes in bone sarcomas: clinical experience with 99Tcm-MDP three-phase dynamic bone scintigraphy. Nucl Med Commun. 1999 Jan;20(1):41-8.
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Diagnosis [E01] | |||||
| Brands: Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: TECHNETIUM (99mTc) MEDRONIC ACID | |||||
| ATC code: V09BA02 | |||||
| Document link: | |||||
| Document date: | |||||
| Study number: | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | - | - | |